Where did these increases come from? Pfizer and the Covid-19 vaccine with over 90% success rate

The American pharmaceutical company Pfizer has just announced that the Covid-19 vaccine developed together with the German BioNTech prevented over 90% of infections in a study of tens of thousands of volunteers. This information and the ending confusion with the election of the new US president made investors euphoric and began to buy shares of listed companies for races.

Pfizer shares are growing by 7% even before the session trading. Stock indices across Europe and futures for US indices are also soaring. German DAX it is more than 6% more expensive during the day. Euphoria reigns in virtually all markets.

DE30 chart (CFD on the DAX30 index), H1 interval. Source: xNUMX XTB.

Analysts say it is influenced by two events. The first is the increasingly clear situation in the US, where everything indicates that the next lawsuits by Donald Trump will not change much and the new US president will be Joe Biden. The end of the electoral confusion - even if the lawyers' scuffles will continue for some time - is always good news for the market.

Check it out: Brokers offering trade on DAX [List]

Pfizer: 90% vaccine efficacy against Covid-19

The statement of the Pfizer company probably caused a big move in stocks of listed companies. While the coronavirus pandemic has already killed 1,2 million people worldwide (although the fact is that the vast majority of them have had comorbidities), Pfizer says the Covid-19 vaccine just works. And it is much better than expected.

“This is probably the best news for the world, the United States and public health. Even we did not expect such a good result, because we expected the effectiveness at the level of 60-70%, and we have over 90%. This is an extraordinary result " - said William Gruber, Pfizer vice president of clinical research and vaccine development.

“It shows that Covid-19 is controllable. Ultimately it is really a victory for science " - added Ugur Sahin, CEO of BioNTech.

It is worth noting, however, that we do not know the detailed data yet. It is not known whether the vaccine will prevent severe disease, as none of the participants who participated in testing it had a severe case of Covid-19.

When will the Covid-19 vaccine be ready?

Moderna Inc, which is in the research phase, uses technology similar to Pfizer's vaccine production. If the results are equally good, two vaccines will be available in the US even by the end of this year.

Now, the data on the side effects, namely the safety of vaccines, is crucial. Pfizer is expected to receive them in the third week of November. Then you will know how your body reacts two months after vaccination. This is almost the last data required by US regulatory authorities and the vaccine will be able to be marketed.

Of course, the vaccine will also go to Europe, because its production is already underway - companies are so sure of the positive news that they did not delay and risked starting their factories earlier. This allows them to produce 1,3 billion doses - enough to vaccinate 650 million people - by the end of 2021. In 2020, 50 million doses will be available.

43 volunteers from many countries took part in the research on its effectiveness. The first trials began in July and a second dose was administered later. Both are based on RNA communication technology that has never been used in an approved drug before. In short: it teaches the body's cells to become natural vaccine factories that reproduce themselves in our body.